



Would you like to use electronic prior authorization? Consider using Surescripts, our electronic prior authorization portal at providerportal.surescripts.net/ProviderPortal/login OR fax completed prior authorization request form to 800-750-9692.

All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned**

Pharmacy Coverage Guidelines are available at sentarahealthplans.com/en/providers/authorizations/prescription-drugs

Verzenio (Medicare)

REQUIRED: Office notes, labs, and medical testing relevant to request showing medical justification to support diagnosis					
Member Information					
Member Name (first & last):		Date of Birth:	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	Height:	
Member ID:	City:		State: Weight:		
Prescribing Provider Information					
Requestor's Name:		Requestor's Phone Number:		Requestor's Fax Number:	
Provider Name (first & last):	Specialty	NPI:	DEA:		
Office Address:		City:		State: Zip Code:	
Office Contact:		Office Phone:		Office Fax:	
Dispensing Provider/Pharmacy Information					
Place of Administration:	<input type="checkbox"/> Self-Administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Home <input type="checkbox"/> Home Infusion Center <input type="checkbox"/> Outpatient Infusion Center Name: _____				
Agency NPI:	Agency Name:		Agency Phone Number:		
Agency Address			Agency Fax Number:		
City:		State:	Zip:		
Dispensing Location:	<input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Mail Order <input type="checkbox"/> Physician's Office <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Other				
Pharmacy Name:		Pharmacy Phone:		Pharmacy Fax:	
Pharmacy NPI:					
Requested Medication Information					
Medication request is NOT for an FDA approved, or compendia-supported diagnosis (check one): <input type="checkbox"/> Yes <input type="checkbox"/> No			Diagnosis:	ICD-10 Code:	
Are there any contraindications to formulary medications? If yes, please specify:			Is this a New Request or Continuation of Therapy: <input type="checkbox"/> New, start date: ____/____/_____ <input type="checkbox"/> Continuation, date of last treatment: ____/____/_____		
Directions for Use:			Strength:	Dosage Form	
			Duration:	Quantity:	Days Supply:
What medication(s) has the member tried and failed for this diagnosis? Please specify below including duration of treatment.					
Turn-Around Time for Review:					
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent: Waiting standard time for decision could seriously harm life, health, or ability to regain maximum function, you can ask for an expedited decision.					
Signature: _____					



Sentara®

Health Plans Member First Name: _____ Member Last Name: _____

Member ID: _____ Member Date of Birth: _____

Clinical Information:

* Indicate questions that are required to be answered

Q1. Please select appropriate diagnosis:

Breast Cancer Other

Q2. For Reauthorization: Has the member responded positively to therapy as determined by the prescribing physician?

Yes No

Q3. For all diagnoses: Is the member's disease hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative as detected by an FDA-approved test?

Yes No

Q4. For all diagnoses: Does the member's disease meet any of the following:

- Member has early breast cancer that is node-positive at high risk of recurrence (e.g. members with greater than or equal to 4 positive lymph nodes or 1-3 positive lymph nodes with one or more of the following: Grade 3 disease or tumor size greater than or equal to 5 cm) and will be using the requested medication in combination with endocrine therapy (i.e. anastrozole, exemestane)
- Member has advanced or metastatic disease and will be using the requested medication in combination with an aromatase inhibitor (i.e. letrozole, anastrozole) as initial endocrine therapy
- Member has advanced or metastatic disease progression following endocrine therapy and will be using the requested medication in combination with fulvestrant
- Member has advanced or metastatic disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. Requested medication will be used as monotherapy
- None of the above